RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Gilead Sciences Employees 2024

Gilead Sciences Employees

13,600

Gilead Sciences Dividend yield

4.47 %

Ticker

GILD

ISIN

US3755581036

WKN

885823

In 2024, Gilead Sciences employed 13,600 people, a 0% change from the 13,600 number of employees in the previous year.

Gilead Sciences Aktienanalyse

What does Gilead Sciences do?

Gilead Sciences Inc, also known as Gilead, is an American biopharmaceutical company specializing in the development and production of drugs. It was founded in 1987 by Michael Riordan and has since become one of the largest biopharmaceutical companies in the world. Gilead focuses on developing drugs for difficult-to-treat diseases such as HIV, hepatitis, cancer, and inflammatory diseases. Its business model is divided into three segments: HIV, liver diseases, and oncology. The company has made significant advancements in antiviral therapies and aims to improve patients' lives and cure diseases through the development of new medical products and therapies. In the HIV segment, Gilead offers drugs such as Truvada, Atripla, and Biktarvy. In liver diseases, the company has focused on fighting hepatitis C and offers drugs like Harvoni, Sovaldi, and Epclusa. In the field of oncology, Gilead develops drugs for cancer treatment, particularly targeting specific mutations. The company has made notable progress in this area, such as developing the first approved CAR-T-cell therapy for lymphoma treatment, Yescarta. Gilead has also gained attention through its innovative research and development work, including licensing the CRISPR-Cas9 technology for targeted gene editing. Overall, Gilead Sciences Inc has had a remarkable success story and is considered one of the most significant biopharmaceutical companies globally, setting standards and bringing hope for cure to many people with serious illnesses. Gilead Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Gilead Sciences revenue by segment

In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.

Employees Details

Examining Gilead Sciences's Employee Base

Gilead Sciences's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Gilead Sciences's operational capacity and future potential.

Year-to-Year Comparison

Assessing Gilead Sciences's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Gilead Sciences's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Gilead Sciences’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Gilead Sciences Stock

How many employees does Gilead Sciences have this year?

Gilead Sciences has 13,600 undefined employees this year.

How many employees did Gilead Sciences have compared to the previous year?

Compared to the previous year, Gilead Sciences had 0% more employees.

What impact did the number of employees have on the company Gilead Sciences?

The number of employees has a direct impact on the efficiency and productivity of Gilead Sciences. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Gilead Sciences?

The number of employees can also have an impact on investors of Gilead Sciences, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Gilead Sciences affect the company?

An increase in equity of Gilead Sciences can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Gilead Sciences's equity affect the company?

A reduction in equity of Gilead Sciences can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Gilead Sciences?

Some factors that can influence the equity of Gilead Sciences include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Gilead Sciences so important for investors?

The equity of Gilead Sciences is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Gilead Sciences influence the company?

The number of employees at Gilead Sciences can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Gilead Sciences evolved in recent years?

In recent years, the number of employees at Gilead Sciences has changed by 0.

How many employees does Gilead Sciences currently have?

Gilead Sciences currently has 13,600 undefined employees.

Why is the number of employees important for investors of Gilead Sciences?

The number of employees is important for investors of Gilead Sciences as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Gilead Sciences take to change the number of employees?

To change the number of employees, Gilead Sciences can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Gilead Sciences pay?

Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 4.47 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.

What is the dividend yield of Gilead Sciences?

The current dividend yield of Gilead Sciences is 4.47 %.

When does Gilead Sciences pay dividends?

Gilead Sciences pays a quarterly dividend. This is distributed in the months of July, October, January, April.

How secure is the dividend of Gilead Sciences?

Gilead Sciences paid dividends every year for the past 15 years.

What is the dividend of Gilead Sciences?

For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.94 %.

In which sector is Gilead Sciences located?

Gilead Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gilead Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gilead Sciences from 3/28/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.

When did Gilead Sciences pay the last dividend?

The last dividend was paid out on 3/28/2024.

What was the dividend of Gilead Sciences in the year 2023?

In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.

In which currency does Gilead Sciences pay out the dividend?

The dividends of Gilead Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Gilead Sciences

Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.